1. Home
  2. OVID vs DCTH Comparison

OVID vs DCTH Comparison

Compare OVID & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ovid Therapeutics Inc.

OVID

Ovid Therapeutics Inc.

HOLD

Current Price

$2.69

Market Cap

562.5M

Sector

Health Care

ML Signal

HOLD

DCTH

Delcath Systems Inc.

HOLD

Current Price

$15.91

Market Cap

578.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OVID
DCTH
Founded
2014
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
562.5M
578.4M
IPO Year
2017
2015

Fundamental Metrics

Financial Performance
Metric
OVID
DCTH
Price
$2.69
$15.91
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
4
Target Price
$4.60
$22.00
AVG Volume (30 Days)
1.4M
421.1K
Earning Date
05-13-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
3.90
107.53
EPS
N/A
0.04
Revenue
$7,252,000.00
N/A
Revenue This Year
N/A
$24.54
Revenue Next Year
$19.34
$33.15
P/E Ratio
N/A
$399.50
Revenue Growth
1181.27
N/A
52 Week Low
$1.12
$8.12
52 Week High
$3.11
$17.42

Technical Indicators

Market Signals
Indicator
OVID
DCTH
Relative Strength Index (RSI) 46.31 50.43
Support Level $2.60 $9.98
Resistance Level $2.77 $17.42
Average True Range (ATR) 0.13 0.41
MACD -0.03 -0.24
Stochastic Oscillator 10.29 12.24

Price Performance

Historical Comparison
OVID
DCTH

About OVID Ovid Therapeutics Inc.

Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.

About DCTH Delcath Systems Inc.

Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

Share on Social Networks: